Regulation catalysts

Regulation catalysts and events, newest first.

DateCardAvg 5d

2026-09-22Paramount and WBD Settle State Antitrust Actions to Accelerate Deal CloseWBD+0.06%
2026-09-22Paramount moves closer to WBD acquisition following state AG antitrust settlementWBD+0.06%
2026-09-22Paramount Settles State AG Lawsuits on WBD Deal with $300M Production PledgePSKY WBD-0.57%
2026-09-22Akkodis and Hamburg Transit Showcase 'hvv mia' AI Platform at InnoTransAHEXY
2026-09-21Fintech Lending Models Diverge as SoFi Deposits Reach $45.5B and Upstart Advances CharterSOFI
2026-09-21PG&E Drops 25% on California SB 492 Amendment Stripping Utility Lawsuit ProtectionsPCG XLU-3.47%
2026-09-21Upstart secures conditional bank charter approval to scale deposit-funded lendingSOFI UPST
2026-09-21PG&E Drops 25% Following California Wildfire Reform Amendment SB 492PCG
2026-09-21PG&E Slides 25% as California SB 492 Removes Insurer Lawsuit ShieldsPCG
2026-09-21Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish TargetsIONS+1.49%
2026-09-21Upstart conditional bank charter approval follows SoFi deposit growth to $45.5BSOFI UPST
2026-09-21California SB 492 amendment strips utility liability protections, hitting PCGPCG
2026-09-21PG&E slides 25% over month following California SB 492 liability amendmentPCG
2026-09-21California amends SB 492 removing utility liability shields against insurance claimsPCG
2026-09-21Fintech Deposit Divergence Grows as Upstart Awaits Bank Charter FinalizationSOFI
2026-09-20Fintech funding models diverge as SoFi deposits hit $45.5B and Upstart eyes charterSOFI
2026-09-20Upstart Advances Conditional Bank Charter Approval to Lower Loan Funding CostsUPST
2026-09-19Bastion secures conditional OCC approval for national trust bank charterMS-3.10%
2026-09-19Teva Real-World Study Shows UZEDY Outperforms Long-Acting InjectablesTEVA
2026-09-16Federal Product Liability Filings Reach 10-Year High on Auto Warranty ClaimsF RELX
2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growthAUTL GILD NVS
2026-09-16University Study Projects Small Modular Reactor Costs at $93/MWh vs $45 Market PricesOKLO SMR
2026-09-15UGAP selects Atos and Thales consortium for 4-year French public cloud contractAEXAY THLLY
2026-09-14FDA Approves Scholar Rock's Isembyld for Spinal Muscular AtrophySRRK
2026-09-13Centene Restructures Medicare Advantage Footprint as Q2 Health Benefits Ratio Reaches 89.5%CNC-1.97%
2026-09-13FDA Approves Scholar Rock's Isembyld for Spinal Muscular AtrophySRRK
2026-09-12FDA approves Scholar Rock's Isembyld for spinal muscular atrophySRRK
2026-09-12Liquidia crosses 5,000 Yutrepia patients amid United Therapeutics patent fightUTHR
2026-09-12Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&ALLY
2026-09-12Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Battle PersistsUTHR
2026-09-12FDA Approves Scholar Rock's Isembyld for Spinal Muscular AtrophySRRK
2026-09-12Liquidia Logs 5,000 Yutrepia Patients Amid Ongoing Litigation with UTHRUTHR
2026-09-11American Water Works Secures $68M New Jersey Rate Increase for Capex PlanAWK WTRG
2026-09-10Meta agrees to $18B multi-state legal settlement and launches Muse AI agentMETA+5.89%
2026-09-10Meta settles multi-state litigation for $18B over 10 years and launches Muse AI agentMETA+5.89%
2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+CRSP VRTX-1.51%
2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MVRTX-1.51%
2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MVRTX-1.51%
2026-09-09CRISPR Therapeutics Casgevy Sales Surge 78% QoQ to $76M Following FDA ExpansionCRSP VRTX-1.51%
2026-09-09Vistra Drops 30% from High Amid PJM Regulatory Scrutiny and Battery OutagesVST
2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76MCRSP
2026-09-09NextEra Secures $1.9B DOE Loan Guarantee for Duane Arnold Nuclear RestartVST
2026-09-09FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy CasgevyCRSP VRTX-1.51%
2026-09-09CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric LabelCRSP VRTX XBI-2.38%
2026-09-09VoIP-Pal Files Third Amended Antitrust Suit Against AT&T, Verizon, T-MobileT TMUS VZ-0.61%
2026-09-09CRISPR Therapeutics Gains FDA Pediatric Approval for Casgevy as Sales Hit $76MCRSP VRTX-1.51%
2026-09-09Vistra Drops 30% to $154 as PJM Scrutiny and Outages Compress ValuationVST
2026-09-08Citigroup Nears Final Regulatory Clearance for Onshore China Brokerage PlatformC
2026-09-08Archer Aviation Completes FAA Phase 3 Milestones for eVTOL Commercial FlightACHR-6.17%
2026-09-07Tesla shares decline 5.9% following Cybercab debut and federal safety auditARKK

See today's live cards

Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

Open Desk — $399/month